5-Fluorouracil and Capecitabine Assessment and treatment of uncommon early-onset severe toxicities associated with administration

被引:13
作者
Brutcher, Edith [1 ]
Christensen, Deb [2 ]
Smith, Melissa Hennessey [3 ]
Koutlas, Judy B. [4 ]
Sellers, Jean B. [5 ]
Timmons, Tahitia [6 ]
Thompson, Joanna [7 ]
机构
[1] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[2] Intermt Canc Ctr, St George, UT USA
[3] Tufts Med Ctr, Boston, MA 02111 USA
[4] Vidant Canc Ctr, Greenville, NC USA
[5] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[6] Cooper Univ Hlth Care, Camden, NJ USA
[7] BTG Int, Hartselle, AL USA
关键词
fluorouracil; capecitabine; uridine triacetate; overdose; side effects; DIHYDROPYRIMIDINE DEHYDROGENASE GENE; URIDINE TRIACETATE; PREVENTION; DEFICIENCY; VARIANTS; REGIMENS; RISK;
D O I
10.1188/18.CJON.627-634
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Uncommon early-onset severe toxicities from 5-fluorouracil (5-FU) and capecitabine can be fatal if early warning signs are not recognized and treated promptly. OBJECTIVES: I his article delineates the differences between expected side effects and uncommon early-onset severe toxicities from 5-FU and capecitabine. It also provides background for understanding the reasons patients may develop these toxicities and reviews the efficacy of standard supportive care against a novel therapy (uridine triacetate). METHODS: A panel of nurses convened to review the literature about toxicities associated with 5-FU and capecitabine administration and determined methods to educate nurses about toxicities and treatment. FINDINGS: Standard supportive care for 5-FU and capecitabine toxicities is associated with high fatality rates. Uridine triacetate treatment within 96 hours of administration is associated with survival.
引用
收藏
页码:627 / 634
页数:8
相关论文
共 29 条
[1]  
Amstutz U, 2011, PHARMACOGENOMICS, V12, P1321, DOI [10.2217/PGS.11.72, 10.2217/pgs.11.72]
[2]  
[Anonymous], 2010, Common terminology criteria for adverse events, v4.03
[3]   Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach [J].
Boisdron-Celle, Michele ;
Capitain, Olivier ;
Faroux, Roger ;
Borg, Christophe ;
Metges, Jean Philippe ;
Galais, Marie Pierre ;
Kaassis, Mehdi ;
Bennouna, Jaafar ;
Bouhier-Leporrier, Karine ;
Francois, Eric ;
Baumgaertner, Isabelle ;
Guerin-Meyer, Veronique ;
Cojocarasu, Oana ;
Roemer-Becuwe, Celia ;
Stampfli, Claire ;
Rosenfeld, Ludovic ;
Lecompte, Thierry ;
Berger, Virginie ;
Morel, Alain ;
Gamelin, Erick .
SEMINARS IN ONCOLOGY, 2017, 44 (01) :13-23
[4]  
BTG International, 2017, VIST UR TRIAC OR GRA
[5]  
Center for Drug Evaluation and Research, 2015, APPL NUMB 208159ORIG
[6]   5-FU-induced neurotoxicity in cancer patients with profound DPD deficiency syndrome: a report of two cases [J].
Cordier, Pierre-Yves ;
Nau, Andre ;
Ciccolini, Joseph ;
Oliver, Manuela ;
Mercier, Cedric ;
Lacarelle, Bruno ;
Peytel, Eric .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (03) :823-826
[7]   New advances in DPYD genotype and risk of severe toxicity under capecitabine [J].
Etienne-Grimaldi, Marie-Christine ;
Boyer, Jean-Christophe ;
Beroud, Christophe ;
Mbatchi, Litaty ;
van Kuilenburg, Andre ;
Bobin-Dubigeon, Christine ;
Thomas, Fabienne ;
Chatelut, Etienne ;
Merlin, Jean-Louis ;
Pinguet, Frederic ;
Ferrand, Christophe ;
Meijer, Judith ;
Evrard, Alexandre ;
Llorca, Laurence ;
Romieu, Gilles ;
Follana, Philippe ;
Bachelot, Thomas ;
Chaigneau, Loic ;
Pivot, Xavier ;
Dieras, Veronique ;
Largillier, Remy ;
Mousseau, Mireille ;
Goncalves, Anthony ;
Roche, Henri ;
Bonneterre, Jacques ;
Servent, Veronique ;
Dohollou, Nadine ;
Chateau, Yann ;
Chamorey, Emmanuel ;
Desvignes, Jean-Pierre ;
Salgado, David ;
Ferrero, Jean-Marc ;
Milano, Gerard .
PLOS ONE, 2017, 12 (05)
[8]   Clinical importance of risk variants in the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine toxicity [J].
Froehlich, Tanja K. ;
Amstutz, Ursula ;
Aebi, Stefan ;
Joerger, Markus ;
Largiader, Carlo R. .
INTERNATIONAL JOURNAL OF CANCER, 2015, 136 (03) :730-739
[9]  
Genentech Inc, 2016, XEL CAP
[10]   Novel Genetic Variants in Carboxylesterase 1 Predict Severe Early-Onset Capecitabine-Related Toxicity [J].
Hamzic, S. ;
Kummer, D. ;
Milesi, S. ;
Mueller, D. ;
Joerger, M. ;
Aebi, S. ;
Amstutz, U. ;
Largiader, C. R. .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 102 (05) :796-804